<PAGE>
As filed with the Securities and Exchange Commission on December 22, 1999
Registration No. 333-
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
MILLENNIUM PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE 04-3177039
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization Identification No.)
75 SIDNEY STREET, CAMBRIDGE MASSACHUSETTS 02139
(Address of Principal Executive Offices) (Zip Code)
LEUKOSITE, INC. AMENDED AND RESTATED 1993 STOCK OPTION PLAN
(Full Title of the Plan)
MARK J. LEVIN
CHIEF EXECUTIVE OFFICER
MILLENNIUM PHARMACEUTICALS, INC.
75 SIDNEY STREET
CAMBRIDGE, MA 02139
(Name and Address of Agent For Service)
(617) 679-7000
(Telephone Number, Including Area Code, of Agent For Service)
<PAGE>
<TABLE>
<CAPTION>
CALCULATION OF REGISTRATION FEE
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
Proposed Proposed
Title of maximum maximum
securities to be Amount to be offering price aggregate offering Amount of
registered registered (1) per share price registration fee
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
<S> <C> <C> <C> <C>
LeukoSite, Inc.
Amended and
Restated 1993
Stock Option
Plan
Common Stock,
$.001 par value 7,616 shares $ 0.0931 (2) $ 709.00 (2) $ 0.19
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
38,124 shares $ 1.4199 (2) $ 54,133.00 (2) $ 14.29
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
655 shares $ 1.6061 (2) $ 1,052.00 (2) $ 0.28
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
1,571 shares $ 1.8389 (2) $ 2,889.00 (2) $ 0.76
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
31,958 shares $ 2.1415 (2) $ 68,439.00 (2) $ 18.07
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
1,138 shares $ 2.1881 (2) $ 2,490.00 (2) $ 0.66
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
4,505 shares $ 2.3277 (2) $ 10,486.00 (2) $ 2.77
- ------------------------ ---------------------- ---------------------- ---------------------- --------------------
11,556 shares $ 2.5605 (2) $ 29,589.00 (2) $ 7.81
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
3,248 shares $ 2.7467 (2) $ 8,921.00 (2) $ 2.36
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
1,309 shares $ 6.0987 (2) $ 7,983.00 (2) $ 2.11
- ------------------------ ---------------------- ---------------------- ----------------------- ---------------------
50,749 shares $11.9181 (2) $ 604,826.00 (2) $159.67
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
1,053 shares $14.2458 (2) $ 14,994.00 (2) $ 3.96
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
56,271 shares $14.3156 (2) $ 805,552.00 (2) $212.67
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
20,718 shares $14.5484 (2) $ 301,419.00 (2) $ 79.57
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
322 shares $15.1304 (2) $ 4,875.00 (2) $ 1.29
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
9,387 shares $15.2770 (2) $ 143,408.00 (2) $ 37.86
- ------------------------ ---------------------- ---------------------- ----------------------- ---------------------
322 shares $15.4213 (2) $ 4,969.00 (2) $ 1.31
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
2,148 shares $15.7123 (2) $ 33,750.00 (2) $ 8.91
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
2,041 shares $16.5852 (2) $ 33,851.00 (2) $ 8.94
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
67,733 shares $16.6899 (2) $ 1,131,125.00 (2) $298.62
- ------------------------ ---------------------- ---------------------- ----------------------- ---------------------
3,920 shares $17.1671 (2) $ 67,297.00 (2) $ 17.77
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
1,504 shares $17.7374 (2) $ 26,678.00 (2) $ 7.04
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
1,074 shares $18.0400 (2) $ 19,375.00 (2) $ 5.12
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
859 shares $18.2263 (2) $ 15,660.00 (2) $ 4.13
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
1,827 shares $18.3310 (2) $ 33,492.00 (2) $ 8.84
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
20,138 shares $18.6220 (2) $ 375,000.00 (2) $ 99.00
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
20,835 shares $19.2039 (2) $ 400,109.00 (2) $105.63
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
2,363 shares $19.4949 (2) $ 46,063.00 (2) $ 12.16
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
16,252 shares $19.6415 (2) $ 319,210.00 (2) $ 84.27
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
2,578 shares $19.7858 (2) $ 51,009.00 (2) $ 13.47
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
3,652 shares $20.0768 (2) $ 73,321.00 (2) $ 19.36
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
322 shares $20.3678 (2) $ 6,563.00 (2) $ 1.73
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
</TABLE>
2
<PAGE>
<TABLE>
<S> <C> <C> <C> <C>
5,456 shares $20.6588 (2) $ 112,713.00 (2) $ 29.76
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
9,022 shares $20.9497 (2) $ 189,018.00 (2) $ 49.90
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
430 shares $21.2407 (2) $ 9,134.00 (2) $ 2.41
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
537 shares $22.6955 (2) $ 12,188.00 (2) $ 3.22
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
430 shares $22.8410 (2) $ 9,822.00 (2) $ 2.59
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
13,747 shares $23.2775 (2) $ 320,000.00 (2) $ 84.48
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
86,350 shares $23.4230 (2) $ 2,022,563.00 (2) $ 533.96
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
4,296 shares $23.5684 (2) $ 101,250.00 (2) $ 26.73
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
2,578 shares $23.8594 (2) $ 61,510.00 (2) $ 16.24
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
31,318 shares $24.1504 (2) $ 756,338.00 (2) $ 199.67
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
860 shares $24.4413 (2) $ 21,021.00 (2) $ 5.55
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
273 shares $24.7323 (2) $ 6,747.00 (2) $ 1.78
- ------------------------ ---------------------- ---------------------- ------------------------ --------------------
752 shares $25.0233 (2) $ 18,823.00 (2) $ 4.97
- ------------------------ ---------------------- ---------------------- ----------------------- ---------------------
64,995 shares $25.8962 (2) $ 1,683,135.00 (2) $ 444.35
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
21,738 shares $26.1872 (2) $ 569,250.00 (2) $ 150.28
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
430 shares $26.7691 (2) $ 11,512.00 (2) $ 3.04
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
15,036 shares $27.0601 (2) $ 406,875.00 (2) $ 107.42
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
430 shares $27.3510 (2) $ 11,762.00 (2) $ 3.11
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
18,043 shares $27.4965 (2) $ 496,113.00 (2) $ 130.97
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
10,740 shares $27.9330 (2) $ 300,000.00 (2) $ 79.20
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
4,081 shares $28.2239 (2) $ 115,118.00 (2) $ 30.41
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
28,697 shares $28.5149 (2) $ 818,300.00 (2) $ 216.03
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
4,296 shares $28.8059 (2) $ 123,750.00 (2) $ 32.67
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
860 shares $29.3878 (2) $ 25,275.00 (2) $ 6.67
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
4,511 shares $29.6788 (2) $ 133,888.00 (2) $ 35.35
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
1,504 shares $29.9697 (2) $ 45,075.00 (2) $ 11.90
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
430 shares $30.2607 (2) $ 13,013.00 (2) $ 3.44
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
55,304 shares $36.3710 (2) $ 2,011,453.00 (2) $ 531.02
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
9,408 shares $36.3710 (2) $ 342,172.00 (2) $ 90.33
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
3,222 shares $37.5349 (2) $ 120,938.00 (2) $ 31.93
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
2,728 shares $37.8259 (2) $ 103,204.00 (2) $ 27.25
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
3,723 shares $38.4078 (2) $ 142,989.00 (2) $ 37.75
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
3,545 shares $46.2640 (2) $ 164,009.00 (2) $ 43.30
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
795 shares $46.2640 (2) $ 36,789.00 (2) $ 9.71
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
382 shares $51.7924 (2) $ 19,780.00 (2) $ 5.22
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
1,504 shares $52.0833 (2) $ 78,335.00 (2) $ 20.68
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
215 shares $60.5214 (2) $ 13,000.00 (2) $ 3.43
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
1,074 shares $65.1769 (2) $ 70,000.00 (2) $ 18.38
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
129,279 shares $98.6563 (3) $12,754,287.00 (3) $3,367.11
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
Total 930,808 shares $28,950,492.00 $7,642.93
- ------------------------ ---------------------- ---------------------- ------------------------ ---------------------
</TABLE>
3
<PAGE>
- -------------------------------------------------------------------------------
(1) The number of shares of Millennium Pharmaceuticals, Inc. common stock to be
issued gives effect to the exchange ratio of 0.4296 shares of Millennium
Pharmaceuticals, Inc. common stock for each share of LeukoSite, Inc. common
stock originally issued under the plan registered hereby, as provided in the
Agreement and Plan of Merger dated October 14, 1999 by and among Millennium
Pharmaceuticals, Inc., ANM, Inc., and LeukoSite, Inc.
(2) Estimated solely for the purpose of calculating the registration fee, and
based upon the fixed exercise prices of outstanding options in accordance with
Rule 457(h) under the Securities Act of 1933, as amended (the "Securities Act").
(3) Computed in accordance with Rules 457(c) and (h) under the Securities Act as
based upon the average of the bid and asked prices on December 22, 1999.
- -------------------------------------------------------------------------------
4
<PAGE>
EXPLANATORY NOTE
This registration statement has been prepared in accordance with the
requirements of Form S-8 under the Securities Act to register 930,808 shares of
the Common Stock of Millennium Pharmaceuticals, Inc., a Delaware Corporation
(the "Registrant") issuable to eligible employees, directors, consultants and
advisors under certain employee benefit plans and written compensation contracts
assumed by Registrant upon the merger of Registrant's wholly-owned subsidiary,
ANM, Inc., a Delaware Corporation, with and into LeukoSite, Inc., a Delaware
corporation. The plans and contracts were previously obligations of LeukoSite,
Inc. and its subsidiaries.
5
<PAGE>
PART I. INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The information required by Part I of Form S-8 is included in documents
sent or given to participants in the plan specified on the cover page of this
Registration Statement, pursuant to Rule 428(b)(1) of the Securities Act of
1933, as amended (the "Securities Act").
PART II. INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. INCORPORATION OF DOCUMENTS BY REFERENCE.
The Registrant is subject to the informational and reporting
requirements of Sections 13(a), 14 and 15(d) of the Securities and Exchange Act
of 1934, as amended (the "Exchange Act"), and in accordance therewith files
reports, proxy statements and other information with the Securities and Exchange
Commission (the "Commission"). The following documents, which are filed with the
Commission, are incorporated in this Registration Statement by reference:
(1) The Registrant's latest annual report filed pursuant to
Section 13(a) or 15(d) of the Exchange Act, or the latest
prospectus filed pursuant to Rule 424(b) under the Securities
Act, which contains audited financial statements for the
Registrant's latest fiscal year for which such statements have
been filed.
(2) All reports filed pursuant to Section 13(a) or 15(d) of the
Exchange Act since the end of the fiscal year covered by the
document referred to in (1) above.
(3) The description of the Common Stock, par value $.001 per share
("Common Stock"), contained in the Registrant's Registration
Statement on Form 8-A filed under the Exchange Act, including
any amendment or report filed for the purpose of updating such
description.
All documents subsequently filed by the Registrant pursuant to Sections
13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a
post-effective amendment which indicates that all shares of Common Stock offered
hereby have been sold or which deregisters all shares of Common Stock then
remaining unsold, shall be deemed to be incorporated by reference herein and to
be part hereof from the date of the filing of such documents. Any statement
contained in a document incorporated by reference herein shall be deemed to be
modified or superseded for purposes of this Registration Statement to the extent
that a statement contained herein or any other subsequently filed document which
also is or is deemed to be incorporated by reference herein modifies or
supersedes such statement. Any statement so modified or superseded shall not be
deemed, except as so modified or superseded, to constitute part of this
Registration Statement.
Item 4. DESCRIPTION OF SECURITIES.
Not applicable.
6
<PAGE>
Item 5.
Not applicable.
Item 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Article EIGHTH of the Registrant's Amended and Restated Certificate of
Incorporation provides that no director of the Registrant shall be personally
liable for any monetary damages for any breach of fiduciary duty as a director,
except to the extent that the Delaware General Corporation Law prohibits the
elimination or limitation of liability of directors for breach of fiduciary
duty.
Article NINTH of the Registrant's Amended and Restated Certificate of
Incorporation provides that a director or officer of the Registrant (a) shall be
indemnified by the Registrant against all expenses (including attorneys' fees),
judgments, fines and amounts paid in settlement incurred in connection with any
litigation or other legal proceeding (other than an action by or in the right of
the Registrant) brought against him by virtue of his position as a director or
officer of the Registrant if he acted in good faith and in a manner he
reasonably believed to be in, or not opposed to, the best interests of the
Registrant, and, with respect to any criminal action or proceeding, has no
reasonable cause to believe his conduct was unlawful and (b) shall be
indemnified by the Registrant against all expenses (including attorneys' fees)
and amounts paid in settlement incurred in connection with any action by or in
the right of the Registrant brought against him by virtue of his position as a
director or officer of the Registrant if he acted in good faith and in a manner
he reasonably believed to be in, or not opposed to, the best interests of the
Registrant, except that no indemnification shall be made with respect to any
matter as to which such person shall have been adjudged to be liable to the
Registrant, unless a court determines that, despite such adjudication but in
view of all of the circumstances, he is entitled to indemnification of such
expenses. Notwithstanding the foregoing, to the extent that a director or
officer has been successful, on the merits or otherwise, including without
limitation, the dismissal of an action without prejudice, he is required to be
indemnified by the Registrant against all expenses (including attorneys' fees)
incurred in connection therewith. Expenses shall be advanced to a director or
officer at his request, provided that he undertakes to repay the amount advanced
if it is ultimately determined that he is not entitled to indemnification for
such expenses.
Indemnification is required to be made promptly unless the Registrant
determines that the applicable standard of conduct required for indemnification
has not been met. In the event the Registrant denies a request for
indemnification, or if the Registrant fails to dispose of a request for
indemnification, or if the Registrant fails to dispose of a request for
indemnification within 60 days after such payment is claimed by the indemnitee,
such person is permitted to petition the court to make an independent
determination as to whether such person is entitled to indemnification. As a
condition precedent to the right of indemnification, the director or officer
must give the Registrant notice of the action for which indemnity is sought and
the Registrant has the right to participate in such action or assume the defense
thereof.
Article NINTH of the Registrant's Amended and Restated Certificate of
Incorporation further provides that the indemnification provided therein is not
exclusive.
7
<PAGE>
Section 145 of the Delaware General Corporation Law provides that a
corporation has the power to indemnify a director, officer, employee or agent of
the corporation and certain other persons serving at the request of the
corporation in related capacities against amounts paid and expenses incurred in
connection with an action or proceeding to which he is or is threatened to be
made a party by reason of such position, if such person shall have acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best
interests of the corporation, and, in any criminal proceeding, if such person
had no reasonable cause to believe this conduct was unlawful; provided that, in
the case of actions brought by or in the right of the corporation no
indemnification shall be made with respect to any matter as to which such person
shall have been adjudged to be liable to the corporation unless and only to the
extent that the adjudicating court determines that such indemnification is
proper under the circumstances.
Item 7. EXEMPTION FROM REGISTRATION CLAIMED.
Not applicable.
Item 8. EXHIBITS.
The Exhibit Index immediately preceding the exhibits is incorporated
herein by reference.
Item 9. UNDERTAKINGS.
1. The Registrant hereby undertakes:
(a) To file, during any period in which offers or sales are being
made, a post-effective amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of
the Securities Act;
(ii) To reflect in the prospectus any facts or events arising
after the effective date of the Registration Statement
8
<PAGE>
(or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental
change in the information set forth in the Registration
Statement. Notwithstanding the foregoing, any increase or
decrease in volume of securities offered (if the total
dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high
end of the estimated maximum offering range may be reflected
in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume
and price represent no more than 20% change in the maximum
aggregate offering price set forth in the "Calculation of
Registration Fee" table in the effective Registration
Statement; and
(iii) To include any material information with respect to the
plan of distribution not previously disclosed in the
Registration Statement or any material change to such
information in the Registration Statement;
PROVIDED, HOWEVER, that paragraphs (a)(i) and (a)(ii) do not apply if
the Registration Statement is on Form S-3 or Form S-8, and the
information required to be included in a post-effective amendment by
those paragraphs is contained in periodic reports filed with or
furnished to the Commission by the Registrant pursuant to Section 13 or
Section 15(d) of the Exchange Act that are incorporated by reference in
the Registration Statement.
(b) That, for the purpose of determining any liability
under the Securities Act, each such post-effective
amendment shall be deemed to be a new Registration
Statement relating to the securities offered therein,
and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.
(c) To remove from registration by means of a
post-effective amendment any of the securities being
registered which remain unsold at the termination of
the offering.
2. That for the purposes of determining any liability under the
Securities Act, each filing of the Registrant's annual report pursuant to
Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each
filing of an employee benefit plan's annual report pursuant to Section 15(d) of
the Exchange Act) that is incorporated by reference in the Registration
Statement shall be deemed to be a new Registration Statement relating to the
securities offered therein, and the offering of such securities at that time
shall be deemed to be in the initial bona fide offering thereof.
3. Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons
of the Registrant pursuant to the foregoing provisions, or otherwise, the
Registrant has been advised that in the opinion of the Commission such
indemnification is against public policy as expressed in the Securities Act and
is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the Registrant of expenses
incurred or paid by a director, officer or controlling person of the Registrant
in the successful defense of any action, suit or proceeding) is asserted by such
director, officer or controlling person in connection with the securities being
registered, the Registrant will, unless in the opinion of its counsel the matter
has been settled by controlling precedent, submit to a court of appropriate
jurisdiction the question of whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the
final adjudication of such issue.
9
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended,
the Registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-8 and has duly caused this
Registration Statement to be signed on its behalf by the undersigned, thereunto
duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the
22nd day of December, 1999.
MILLENNIUM PHARMACEUTICALS, INC.
By: /s/ MARK J. LEVIN
--------------------------------
Mark J. Levin
Chief Executive Officer
POWER OF ATTORNEY
We, the undersigned officers and directors of Millennium
Pharmaceuticals, Inc. hereby severally constitute and appoint Mark J. Levin and
Kevin P. Starr, and each of them singly, our true and lawful attorneys with full
power to them, and each of them singly, to sign for us and in our names in the
capacities indicated below, the Registration Statement on Form S-8 filed
herewith and any and all subsequent amendments to said Registration Statement,
and generally to do all such things in our names and behalf in our capacities as
officers and directors to enable Millennium Pharmaceuticals, Inc. to comply with
all requirements of the Securities and Exchange Commission, hereby ratifying and
confirming our signatures as they may be signed by said attorneys, or any of
them, to said Registration Statement and any and all amendments thereto.
10
<PAGE>
Pursuant to the requirements of the Securities Act of 1933, as amended,
this Registration Statement has been signed below by the following persons in
the capacities and on the date indicated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
<S> <C> <C>
/s/ Mark J. Levin Chairman of the Board and Chief December 22, 1999
--------------------------- Executive Officer (Principal
Mark J. Levin Executive Officer)
/s/ Kevin P. Starr Chief Financial Officer (Principal December 22, 1999
--------------------------- Financial and Accounting Officer)
Kevin P. Starr
/s/ Joshua Boger Director December 22, 1999
---------------------------
Joshua Boger, Ph.D
/s/ Eugene Cordes Director December 22, 1999
---------------------------
Eugene Cordes, Ph.D
/s/ A. Grant Heidrich Director December 22, 1999
---------------------------
A. Grant Heidrich, III
/s/ Raju S. Kucherlapati Director December 22, 1999
---------------------------
Raju S. Kucherlapati, Ph.D
/s/ Eric S. Lander Director December 22, 1999
---------------------------
Eric S. Lander, Ph.D
/s/ Steven C. Wheelwright Director December 22, 1999
---------------------------
Steven C. Wheelwright
</TABLE>
11
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
- ------- -----------
<S> <C>
4.1 Amended and Restated Certificate of Incorporation of the Registrant
(incorporated herein by reference to Exhibit 4.1 to the Registrant's
Quarterly Report on Form 10-Q, Filed June 20, 1996).
4.2 Restated By-Laws of the Registrant (incorporated herein by reference to
Exhibit 4.2 to the Registrant's Quarterly Report on Form 10-Q, Filed June 20,
1996).
5 Opinion of Hale and Dorr LLP
23.1 Consent of Hale and Dorr LLP (included in Exhibit 5)
23.2 Consent of Ernst & Young LLP
24.1 Power of Attorney (included in the signature pages of this Registration
Statement)
</TABLE>
<PAGE>
Counsellors at Law
60 State Street, Boston, Massachusetts 02109
617-526-6000 - fax 617-526-5000
EXHIBIT 5
December 22, 1999
Millennium Pharmaceuticals, Inc.
75 Sidney Street
Cambridge, MA 02139
Re: LEUKOSITE, INC. AMENDED AND RESTATED 1993 STOCK OPTION PLAN
Ladies and Gentlemen:
We have assisted in the preparation of a Registration Statement on Form
S-8 (the "Registration Statement"), to be filed with the Securities and Exchange
Commission, relating to an aggregate of 930,808 shares of common stock, $.001
par value per share (the "Shares"), of Millennium Pharmaceuticals, Inc., a
Delaware corporation (the "Company"), issuable under the above referenced plan
(the "Plan").
We have examined the Amended and Restated Certificate of Incorporation
and the Amended and Restated By-Laws of the Company, and amendments thereto, the
Registration Statement, and originals, or copies certified to our satisfaction,
of such records of meetings, written actions in lieu of meetings, or resolutions
adopted at meetings of the directors of the Company, and such other documents
and instruments as in our judgment are necessary or appropriate to enable us to
render the opinions expressed below.
In our examination of the foregoing documents, we have assumed the
genuineness of all signatures and the authenticity of all documents submitted to
us as originals, the conformity to original documents of all documents submitted
to us as certified or photostatic copies, and the authenticity of the originals
of such documents.
Based upon and subject to the foregoing, we are of the opinion that the
shares covered by the Registration Statement to be issued under the Plan have
been duly and validly authorized for issuance, and when issued in accordance
with the terms of the Plan, will be legally issued, fully paid and
nonassessable.
<PAGE>
We hereby consent to the filing of this opinion with the Securities and
Exchange Commission as an Exhibit to the Registration Statement.
Very truly yours,
/s/ Hale and Dorr LLP
---------------------
HALE AND DORR LLP
<PAGE>
EXHIBIT 23.2
CONSENT OF INDEPENDENT AUDITORS
We consent to the incorporation by reference in the Registration
Statement (Form S-8) pertaining to the registration of 930,808 shares of
common stock under the LeukoSite, Inc. Amended and Restated 1993 Stock Option
Plan of our report dated February 9, 1999 with respect to the consolidated
financial statements of Millennium Pharmaceuticals, Inc. included in its
Annual Report (Form 10-K) for the year ended December 31, 1998, filed with
the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Ernst & Young LLP
Boston, Massachusetts
December 21, 1999
